MILAN (AIMnews.it) - Bomi Italia's Board of Directors approved the "stand alone" business plan 2018-2020. In light of a proforma 2017 (considering the contribution of the Brazilian subsidiary for the entire year) that should close with almost 120 million euros in turnover, the managers of the biomedical logistics group are aiming for over 125 million consolidated revenues this year ( with over 12.5 million ebitda), which should then reach around 140 million next year (with an ebitda of over 15 million) and exceed 150 million at the end of the plan, with an expected ebitda above 16.5 million . After investments estimated at almost 6 million this year and around 3 million in the next two years, the ratio between net financial position and ebitda, thanks to cash generation, should decrease from 2.01 times in 2018 to 0.5 times in 2020. The business plan, explains the company note, "reflects the current structure and scope, without considering further M & A transactions or the acquisition or loss of significant commercial contracts.